FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2960419095> ?p ?o ?g. }

• W2960419095 abstract "Death receptor 3 (DR3) is a tumor necrosis factor receptor superfamily member (TNFRSF25), which is minimally expressed on resting conventional T cells (though readily inducible upon cell activation), yet highly expressed on resting FoxP3+ regulatory T cells (Treg). We recently demonstrated that activation of DR3 with an agonistic antibody (4C12) leads to selective expansion and activation of Treg in healthy mice and suppression of graft-versus-host disease (GVHD) in recipient mice when donor mice are treated. However, given the long antibody half-life and concomitant safety concerns, along with the lack of a humanized agonistic antibody to DR3, both human and murine fusion proteins incorporating the natural DR3 ligand TL1A (TL1A-Ig) have been developed. Herein, we show that DR3 activation with 4C12 or with TL1A-Ig, with or without the addition of low dose IL-2 to the treatment regimen, led to a significant expansion of murine Treg in spleen, lymph nodes, and peripheral blood. Bioluminescent imaging revealed peak Treg expansion around day 7-8, with return to near baseline after 2-3 weeks. In addition to expansion, all DR3 agonist treatment regimens led to increased activation of Tregs, with significant upregulation of the activation markers ICOS, KLRG-1, PD-1, and CD103, and the proliferation marker Ki-67. The absence of activated Treg populations in control treated spleens was also detected on tSNE analysis of flow cytometry data. Subtly different patterns of splenic Treg activation by the different DR3 agonists were noted in both tSNE analysis of flow cytometry data and RNA-sequencing analysis. However, upregulation of gene transcripts which play important roles in cell proliferation, trafficking, activation, and effector function were observed regardless of the DR3 agonist treatment regimen used. In the major MHC-mismatch model of hematopoietic cell transplantation, DR3 agonist-mediated expansion and activation of Tregs in donor mice led to a significant improvement in GVHD in recipient mice. These data provide important preclinical information regarding the outcome of DR3 activation with an agonistic antibody or natural ligand and provide insight into the therapeutic use of this approach to reduce GVHD in recipients and improve outcomes of hematopoietic cell transplantation." @default.
• W2960419095 created "2019-07-23" @default.
• W2960419095 creator A5005492422 @default.
• W2960419095 creator A5047683451 @default.
• W2960419095 creator A5049731275 @default.
• W2960419095 creator A5051930832 @default.
• W2960419095 creator A5053387814 @default.
• W2960419095 creator A5064778193 @default.
• W2960419095 creator A5071038687 @default.
• W2960419095 creator A5077148194 @default.
• W2960419095 creator A5082957036 @default.
• W2960419095 creator A5090435126 @default.
• W2960419095 date "2019-07-17" @default.
• W2960419095 modified "2023-10-03" @default.
• W2960419095 title "Activation of the DR3-TL1A Axis in Donor Mice Leads to Regulatory T Cell Expansion and Activation With Reduction in Graft-Versus-Host Disease" @default.
• W2960419095 cites W1481752884 @default.
• W2960419095 cites W1507819876 @default.
• W2960419095 cites W1544331058 @default.
• W2960419095 cites W1947330042 @default.
• W2960419095 cites W1975673961 @default.
• W2960419095 cites W1978824927 @default.
• W2960419095 cites W1981690705 @default.
• W2960419095 cites W1986741896 @default.
• W2960419095 cites W1995871393 @default.
• W2960419095 cites W2000328513 @default.
• W2960419095 cites W2006563647 @default.
• W2960419095 cites W2036736974 @default.
• W2960419095 cites W2041355950 @default.
• W2960419095 cites W2041589295 @default.
• W2960419095 cites W2047526240 @default.
• W2960419095 cites W2052766909 @default.
• W2960419095 cites W2055530308 @default.
• W2960419095 cites W2055588490 @default.
• W2960419095 cites W2070050178 @default.
• W2960419095 cites W2070151667 @default.
• W2960419095 cites W2071178658 @default.
• W2960419095 cites W2073045132 @default.
• W2960419095 cites W2085704445 @default.
• W2960419095 cites W2105132195 @default.
• W2960419095 cites W2109509381 @default.
• W2960419095 cites W2119860862 @default.
• W2960419095 cites W2124889735 @default.
• W2960419095 cites W2125594832 @default.
• W2960419095 cites W2145702878 @default.
• W2960419095 cites W2150888933 @default.
• W2960419095 cites W2157325100 @default.
• W2960419095 cites W2162170222 @default.
• W2960419095 cites W2163862604 @default.
• W2960419095 cites W2175868602 @default.
• W2960419095 cites W2179438025 @default.
• W2960419095 cites W2345356016 @default.
• W2960419095 cites W2402789890 @default.
• W2960419095 cites W2533485533 @default.
• W2960419095 cites W2589911436 @default.
• W2960419095 cites W2782231020 @default.
• W2960419095 cites W2801754298 @default.
• W2960419095 cites W2899447277 @default.
• W2960419095 doi "https://doi.org/10.3389/fimmu.2019.01624" @default.
• W2960419095 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6652149" @default.
• W2960419095 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31379829" @default.
• W2960419095 hasPublicationYear "2019" @default.
• W2960419095 type Work @default.
• W2960419095 sameAs 2960419095 @default.
• W2960419095 citedByCount "13" @default.
• W2960419095 countsByYear W29604190952019 @default.
• W2960419095 countsByYear W29604190952020 @default.
• W2960419095 countsByYear W29604190952021 @default.
• W2960419095 countsByYear W29604190952022 @default.
• W2960419095 crossrefType "journal-article" @default.
• W2960419095 hasAuthorship W2960419095A5005492422 @default.
• W2960419095 hasAuthorship W2960419095A5047683451 @default.
• W2960419095 hasAuthorship W2960419095A5049731275 @default.
• W2960419095 hasAuthorship W2960419095A5051930832 @default.
• W2960419095 hasAuthorship W2960419095A5053387814 @default.
• W2960419095 hasAuthorship W2960419095A5064778193 @default.
• W2960419095 hasAuthorship W2960419095A5071038687 @default.
• W2960419095 hasAuthorship W2960419095A5077148194 @default.
• W2960419095 hasAuthorship W2960419095A5082957036 @default.
• W2960419095 hasAuthorship W2960419095A5090435126 @default.
• W2960419095 hasBestOaLocation W29604190951 @default.
• W2960419095 hasConcept C104317684 @default.
• W2960419095 hasConcept C126322002 @default.
• W2960419095 hasConcept C127561419 @default.
• W2960419095 hasConcept C17991360 @default.
• W2960419095 hasConcept C203014093 @default.
• W2960419095 hasConcept C2776090121 @default.
• W2960419095 hasConcept C2779727006 @default.
• W2960419095 hasConcept C2779972918 @default.
• W2960419095 hasConcept C2780931953 @default.
• W2960419095 hasConcept C2911091166 @default.
• W2960419095 hasConcept C502942594 @default.
• W2960419095 hasConcept C553184892 @default.
• W2960419095 hasConcept C55493867 @default.
• W2960419095 hasConcept C71924100 @default.
• W2960419095 hasConcept C86803240 @default.
• W2960419095 hasConcept C8891405 @default.
• W2960419095 hasConceptScore W2960419095C104317684 @default.
• W2960419095 hasConceptScore W2960419095C126322002 @default.
• W2960419095 hasConceptScore W2960419095C127561419 @default.
• W2960419095 hasConceptScore W2960419095C17991360 @default.

• next